Q3 2024 Zoetis Inc Earnings Call
Hum.
[music].
Please stand by your program is about to begin do you need assistance on today's program. Please press Star zero.
Speaker Change: Welcome to the third quarter 2024 financial results conference call and webcast or so wettest hosting the call today is Steve Frank Vice President of Investor Relations Sports awareness.
The presentation materials and additional financial tables are currently posted on the Investor Relations section of <unk> Dot com.
The presentation slides can be managed by you the viewer and will not be forwarded automatically.
Speaker Change: In addition, a replay of this call will be available approximately two hours. After the conclusion of this call via dial in or on the Investor Relations section of <unk> Dot com.
At this time, all participants have been placed in a listen only mode and the floor will be opened for your questions. Following the presentation.
If you'd like to ask a question at that time. Please press star one on your telephone keypad. If at any point. Your question has been answered you may remove yourself from the queue by pressing star two.
In the interest of time, we ask that you limit yourself to one question and then queue up again with any follow ups your.
Your line will be muted when you complete your question.
When posing your question. Please pickup your handset to allow optimal sound quality.
Lastly, if you should require operator assistance, please press star zero.
It is now my pleasure to turn the floor over to Steve Frank Steve You may begin.
Steve Frank: Thank you operator, good morning, everyone and welcome to the <unk> third quarter 2024 earnings call I'm joined today by Kristin Peck, our Chief Executive Officer, and Whitney Joseph Our Chief Financial Officer before we begin I'll remind you that the slides presented on this call are available on the Investor Relations section of our website.
Speaker Change: And that our remarks today will include forward looking statements and that actual results could differ materially from those projections.
Speaker Change: For a list and description of certain factors that could cause results to differ I refer you to the forward looking statement in today's press release, and our SEC filings, including but not limited to our annual report on Form 10-K, and our reports on Form 10-Q.
Our remarks today will also include references to certain financial measures, which were not prepared in accordance with generally accepted accounting principles or U S. GAAP.
Speaker Change: A reconciliation of these non-GAAP financial measures to the most directly comparable U S. GAAP measures is included in the financial tables that accompany our earnings press release and the company's 8-K filing dated today Monday November four 2024.
We also cite operational results, which exclude the impact of foreign exchange.
And with that I will turn the call over to Kristen. Thank you, Steve and good morning, everyone. Thank you for joining our 2024 third quarter earnings call. Let me start by thanking our dedicated purpose driven colleagues, who helped us deliver another excellent quarter building on the strong momentum from the first half of the year revenue grew 14% operationally.
Speaker Change: And adjusted net income is up 15% operationally, we saw balanced double digit growth across the business driven by steady demand for our key franchises U S grew 15% and international revenue grew 13% operationally our innovative companion animal portfolio grew 15% operationally.
Speaker Change: While livestock grew 11% on an operational basis, Arkansas.
Speaker Change: Our consistent growth is fueled by a diverse durable and science driven portfolio carefully crafted through a deep understanding of our customers' evolving needs.
Speaker Change: By maintaining a strong focus on innovation, we set the standard for improving patient outcomes higher customer satisfaction and strong partnerships with veterinarians and pet owners are osteoarthritis pain franchise labella until FCS continues to make a transformative impact by addressing a critical unmet need.
97% operational revenue growth globally.
Speaker Change: From our conversations with customers around the world. It is clear that our safe effective solutions are making a meaningful difference in patients' lives.
Speaker Change: We recognize the profound impact of our work, which only strengthens our commitment to developing this market. We have navigated this path before and understand that building a new category of care requires a steady strategic approach.
Speaker Change: As we lap the U S. Labella launch we continue to grow share even in a market where canine pain visits typically slow down from Q2 to Q3 in fact, the brown is actively disrupting this trend by driving more clinic visits and increasing engagement.
Speaker Change: With $55 million in U S quarterly sales, we see significant opportunity to further expand share and utilization in just 11 months, we have treated 1 million.
Speaker Change: Compared to an estimated 8 million receiving other treatments and Nebraska has already become the fourth largest product in U S pet care.
Speaker Change: This highlights the demand and long term growth potential reinforcing our confidence in the franchise's billion dollar trajectory.
Speaker Change: With record market penetration in the U S. We're only scratching the surface of broader utilization potential we estimate that an additional 17 million are suffering from untreated OE.
Speaker Change: That's because before and the breath and says we're the only option for that which many untreated dov could not tolerate due to preexisting conditions.
Speaker Change: Globally, the abella opportunity is equally significant with OA pain estimated to affect nearly 40% of dogs and importantly in the U S. We see a similar non linear growth curve to Europe, where revenue grew 18% operationally year over year in year four of lunch.
Given our results there we are poised to create and expand this market domestically drawn on that experience is key to positioning labella as the preferred pain treatment by highlighting its safe effective and convenient choice for that we will leverage our strong partnerships and continue collaborating with veterinarians to expand treatment adoption shifting away.
<unk> from two decades of reliance on Nsaids.
Speaker Change: <unk> and trends like these reaffirm what we've long understood the human animal bond is undeniable.
Today's generation of pet owners do their pets as integral members of their family and expect human quality care monoclonal antibody increasingly important in human health are a prime example of how we're bringing that same kind of innovation to animal health with treatments like liberal until Ses <unk>.
Speaker Change: Paragon franchise continues to deliver impressive results as well growing 27% operationally, while our science backed innovation have created entirely new categories in animal health. We have also set the standard for competing in established market through close collaboration with customers, we understood that overcoming first mover.
Speaker Change: Advantage requires to differentiation and long term loyalty is earned with products that standout in both safety and efficacy. The success of our comparative franchise expanded the total parasiticide market and demonstrated that improving patient outcomes is not zero sum, especially with a significant.
Speaker Change: <unk> needs in 2020, we pioneered the use triple combination parricide market with <unk> trio offering comprehensive protection against fleas tick and heartworm and one monthly chewable trio is now the number one that prescribed parasiticide with over 13 million dogs treated in just four years at 86 person.
Speaker Change: I had a pet owners report high satisfaction. Despite increased competition trio prescription rates continue to climb as triple combination products are gaining share supported by our field forces scale, and excellence and driving customer engagement and our commitment to making our products accessible to the most convenient channels, where pet owners has solidified.
Speaker Change: <unk> trios retail leadership.
Speaker Change: Looking ahead to 2025, we anticipate a dynamic landscape, but proceed two key outcomes first consistent with historic trends. The overall addressable market will grow second having more auctions will accelerate education, that's and pet owners, increasing awareness of the benefits of broad spectrum protection will drive <unk>.
<unk> the triple combination treatments.
Speaker Change: With our significant head start proven efficacy and convenience along with our trusted relationships. We believe <unk> will remain the preferred choice, even as new products enter the market. Similarly, 16% operational revenue growth across our key terminology franchise demonstrates how disruptive innovation and strategic life.
Speaker Change: Cycle enhancement drive sustained growth over a decade ago, we identified a crucial unmet need in veterinary medicine, a solution for canine dermatological edge, the balance safety and efficacy it impacts the well being of both pets and their owners, it's heartbreaking to see dock struggling to find relief from persistent discomfort.
We were first to address this challenge thanks to our relentless focus on innovation and execution in just a decade the market grew from $70 million to over $1 5 billion and growing but we did just enter the market. We built it cultivated and continuously about that clearly the industry's first billion dollar.
Franchise.
Speaker Change: As a result today Apple quell is the number one prescribed medication and animal health in the market and our customers have grown alongside us and when that's wanted other options. We delivered truly differentiated first line treatments like <unk>. The first monoclonal antibody to treat edge and ethical chew a convenient shoe.
Speaker Change: Will that enhances compliant.
Speaker Change: These therapies are trusted by veterinarians worldwide, bringing relief to over $23 million globally, and we believe they are the best treatment options and it's not only our product portfolio that sets us apart is our coast customer focused approach to development.
Speaker Change: Trust, our product for their rigorous safety standards and confidence and dosing regimens that allow for chronic uninterrupted use.
Speaker Change: Our research driven approach to JAK inhibition selectively ensured that our treatments can be used safely alongside other medications, including vaccines.
With over 20 million dogs globally, with untreated or Undertreated edge, the derm market growth potential is bass, our proven performance reflects our commitment to expanding access and providing trusted first line solutions.
Speaker Change: Similar to our experience in Paris, we expect Optionality will grow the overall market a market, whereas the wettest has to first line treatments that are known for being safe effective and trusted even with alternatives satisfied satisfied customers are far less likely to switch and we continue to deliver the solutions They trust and rely on.
Speaker Change: Innovation execution and a relentless focus on customer needs are the cornerstone of our key market leading franchises.
Speaker Change: Turning to livestock, we recently closed the sale of our medicated feed additives and certain water soluble product portfolios to fiber of animal health. This transaction is a prime example of the way. This is disciplined capital allocation strategy, allowing us to focus our investments on areas with the highest growth potential align with our core capabilities.
Speaker Change: We remain deeply committed to livestock sharpening our focus on key areas of innovation, including preventative antibiotic alternatives and genetics. For example in September we announced a strategic partnership with Danone to leverage the wettest as genetic testing capabilities and promoting sustainable dairy production.
Speaker Change: This collaboration aims to help dairy producers and juno's global supply chain improve animal health and productivity with a focus on animal well being this strengthened long term industry resilience, while also reducing environmental impact looking ahead, we anticipate the livestock industry to grow 2% to 4% annually.
Speaker Change: We aim to be at the higher end of that range innovation will be a key driver of that growth.
Speaker Change: And to that end, we've updated our guidance to reflect strong performance across our key franchises along with impacts primarily from the MFA divestiture Whitney will dive into the details there.
Speaker Change: With 12% operational revenue growth through the first three quarters, we have outpaced our initial expectations, a testament to our agility and navigating a complex environment.
Speaker Change: As we look to Q4, we anticipate a return to our previous levels of above market growth and remain on track to meet our revised full year guidance with strong momentum going into 2025. This quarter's results highlight the strength of our diverse durable portfolio and unwavering commitment to delivering for our customers before I close.
Speaker Change: I want to extend my sincere gratitude to our colleagues they embody our purpose support our customers and drive our exceptional performance. Their dedication is what truly makes a difference.
Speaker Change: With their passion and commitment we feel positive about our ability to deliver on the four key tenants of our value proposition to grow revenue faster than the market to invest in innovation and growth capabilities to grow adjusted net income faster than revenue and to return excess capital to shareholders with that I'll turn it over to Whitney.
Whitney Joseph: Thank you Kristen and good morning, everyone.
Whitney Joseph: To reiterate innovation and execution underpinned an excellent third quarter, driven by the strength of our diverse and differentiated portfolio.
Whitney Joseph: Another quarter of double digit operational growth across species and geographies.
Whitney Joseph: The remarkable performance of our companion animal portfolio highlights the willingness of pet owners to spend on the health and wellbeing of their pets and the value of our products to pet owners and veterinary practices.
Whitney Joseph: Our lifestyle growth underscores the essential and growing need for animal protein around the world and the important role our products play in helping producers keep their herds healthy.
Whitney Joseph: Put simply we provide critical solutions central to animal health.
Speaker Change: Our success is directly tied to our customers and our first to market innovations continue to fuel the growth and success of their practices.
Speaker Change: In the third quarter, we posted $2 $4 billion in revenue growing 11% on a reported basis and 14% operationally with 8% driven by volume and 6% from price.
Speaker Change: Adjusted net income of $760 million grew 14% on a reported basis and 15% operationally.
Speaker Change: Revenue growth in the quarter was driven by our innovative companion animal portfolio.
Globally.
Speaker Change: <unk> contributed $151 million awesome Burger franchise posted $333 million and our key dermatology franchise contributed revenue of $449 million.
Speaker Change: Our lifestyle portfolio also contributed strong growth with $758 million in revenue.
Speaker Change: Regarding our OA pain maps, the grella insulins.
In Europe. After just three five years on the market Labella Insulins here are the leading treatment for OA pain and are driving market expansion by broadening treatment options across cases.
As Christian mentioned many of these patients with previously untreated because they could not tolerate handsets.
Speaker Change: In Europe and the U S.
<unk> expansion into this patient group represents a significant market growth opportunity.
Speaker Change: In the U S. The growing importance of maps cannot be understated.
Speaker Change: While overall U S clinic visits are down, particularly for prescription only visits that are moving to alternative channels therapeutic visits such as those fall away are on the rise.
Speaker Change: In the U S. The gorilla has.
Almost half a million new patients to the OA pain category since launch by expanding the market with a new standard of care.
Our performance within the <unk> franchise highlights our ability to meet the evolving needs needs of pet owners by delivering safe and effective products to convenient channels, such as retail where trio is a top selling pharmaceutical.
Firstly decides it's the largest most competitive therapeutic category in animal health and we have substantially increased our market share by being the first to market in the U S with a trusted differentiated product.
Since the launch of <unk> trio.
We have gone from number five in this category to number two with clear triple combination market leadership.
And in the first year of competition in U S. Triple combinations, we grew revenue by more than 25% and increased our market share.
Okay.
In the U S. We estimate almost 60% of Medicalized dogs are not on triple combination products.
Speaker Change: The increased share of voice from new entrants should accelerate the shift to triple combinations, where we have a first to market advantage.
Speaker Change: We continue to win with puppies with trio is the preferred choice for these new patients signaling strong growth potential.
Speaker Change: Earlier Christian highlighted the deliberate balance between safety and efficacy with our key dermatology products <unk>.
<unk> delivered on that and quickly became one of the most important products in clinics.
We understood our customers wanted more convenient options for derm treatment and we delivered.
We have multiple derm products with unique value propositions for both the vet and the pet owner.
Speaker Change: All of our products can be used on acute seasonal and chronic cases and have years of real world vet and pet owner satisfaction.
As we face new competition, we remain confident in our growth trajectory.
Speaker Change: We have proven experience defending established brands and we are confident that our portfolio of first line treatments will remain among the most important products in vet clinics.
Now, let's move to segment results.
Speaker Change: U S revenue grew 15% in the quarter with companion animal growing 18% and livestock growing 5%.
U S companion companion animal performance was driven by a whole ethane labs, including the launch of labella as well as continued adoption and compliance of Simpatico trio and all key dermatology franchise.
Speaker Change: We continue to grow above market driven by increased therapeutic treatment for OA and dermatology veterinarians preference for Injectables and evolving pet owner preference for retail convenience and home delivery, which also boost compliance.
With all medications.
Speaker Change: Oh, Hey, Matt the Ghrelin Celesio posted a combined $73 million in U S sales in Q3.
The boiler generated $55 million, primarily on increased clinical utilization.
Attrition has reached 85% faster than any product in our history.
A crucial first step in a successful launch was ensuring clinic availability.
And again, we are just scratching the surface with OE, just as we've seen with our key dermatology franchise addressing unmet needs with revolutionary treatment can deliver long term growth and we believe labella will be a growth tailwind for years ahead.
Valencia posted a $2 million in revenue or 50% growth.
Speaker Change: While the incidence rates for all in cost is similar to dogs at around 40%.
There were very few treatment options for cats prior to Cynthia.
Speaker Change: Since the <unk> launch in the U S. Two years ago, we have seen few line OA patients increased over 70%.
With current feline medicalization rates significantly lower than dogs boosting fee line treatment presents a significant untapped opportunity.
<unk> growth of 29% with $237 million in revenue.
Speaker Change: We previously highlighted trios momentum through the first year with competition and our expectations remain high.
As we've seen with previous generations of parasiticide secondary entrants serve to accelerate conversion from older therapies, but in the absence of meaningful differentiation, they do not erode market share.
In addition to robust volume growth growth for trio, we continue to see the benefit of price driven by our lower promotional environment.
And more thoughtful discounting across our customer base.
Speaker Change: In U S key dermatology, we saw 17% growth or $303 million for the quarter.
<unk> was the largest driver with outsized contributions from the retail channel.
<unk> growth outpaced tablet cannibalization declines benefitting from increased conversion and compliance.
So I had a point of growth continues to be driven by preference for injectables.
U S livestock grew 5% in the quarter, primarily driven by volume growth in cattle, where we continue to see improved supply supply of substance here.
Speaker Change: This growth was partially offset by Jackson price declines.
Speaker Change: Moving on to our International segment revenue grew 7% on a reported basis and 13% operationally in the quarter.
International livestock, we're 15% operational and companion animal grew 11% operationally.
Speaker Change: And a national lifestyle grew 15% operationally in the quarter with equal contribution from volume and price.
<unk> was the largest growth contributor driven by the impact of price and high inflationary markets as well as volume growth from higher demand and improved supply.
Speaker Change: Poultry growth was driven by price and key account penetration.
Speaker Change: Lastly, fish, so strong volume growth in Norway, driven by high demand for our vaccines as well as the impact of a soft comparable period last year.
Speaker Change: International Companion animal growth was driven by our <unk> key dermatology and OA pain Mab franchises.
Speaker Change: Our international <unk> franchise grew 28% operationally with $75 million in sales.
Performance was driven by some product the trio growing 39% operationally to $31 million in sales benefited benefiting from key account growth in Europe, DTC and the positive impact of our Q1, China launch.
Speaker Change: The parka with 22% operationally on $44 million in sales driven primarily by eastern Europe and Brazil.
Our international key dermatology franchise contributed $146 million of revenue, 13% operational growth with double digit operational growth in Africa and cider point.
Growth was driven by applicable with strong DTC success, especially in European markets.
Europe is also benefiting from strong adoption of Africa, Chewable, where we now see more than half of doses dispensed coming from the chewable formulation.
Our key dermatology franchise continues to expand internationally. Many countries are still in the early stages of <unk> market development and increases in medical position as well as the benefits that <unk> and Injectables can offer provide a significant runway for growth.
Speaker Change: Internationally, our <unk> grew 27% operational posting $78 million in combined revenue.
International sales of Labella were $62 million growing 26% operationally.
Speaker Change: Well Wella was driven by higher use in Europe, as well as market expansion and share gains and second wave launch markets.
We see opportunity for continued market expansion from converting existing <unk> patients and increasing months on therapy.
Speaker Change: So, let's see yourselves were $16 million growing 32% on an operational basis.
Speaker Change: Now moving on to the P&L for the quarter adjusted.
Adjusted gross margin of 77% grew 20 basis points with increases from price and mix offset by higher manufacturing costs.
Adjusted operating expenses increased 9% operationally.
Speaker Change: Growth was driven primarily by SG&A expenses of 9% operationally largely due to higher compensation related expenses due to company performance.
Speaker Change: R&D grew 10% operationally in the quarter on higher compensation related expenses due to company performance and increases in project spend related to internal portfolio advancements.
Adjusted net income grew faster than revenue at 15% operational.
Speaker Change: Adjusted diluted EPS grew 17% operationally for the quarter.
Speaker Change: Now moving onto guidance for the full year 2024.
Speaker Change: Our raised revenue guidance reflects continued strong performance of our key franchises, partially offset by a reduction to sales for the divestiture of our medicated feed additive product portfolio and certain water soluble products completed October 31.
Speaker Change: As Christa highlighted we remain committed to lifestyle and see opportunities in several therapeutic areas enhanced by our strategic partnerships and focus.
Speaker Change: Please note that guidance reflects foreign exchange rates as of mid October.
Speaker Change: For the year, we expect revenue between $9 to $9 $3 billion a.
Speaker Change: The range of 10% to 11% operational growth.
Speaker Change: This is both an increase and a narrowing of our revenue range versus our prior full year guidance.
Speaker Change: We now expect adjusted net income to be in the range of $2 67 to $2 $6 $95 billion.
Speaker Change: Representing operational growth of 13, 5% to 14, 5%.
Speaker Change: Finally, we expect adjusted diluted EPS to be in the range of $5 86 to.
Speaker Change: To $5 92.
Speaker Change: And reported diluted EPS to be in the range of $5 33 to.
Speaker Change: To $5 39.
Speaker Change: Okay.
Speaker Change: We have seen outstanding performance in 2024, thus far with broad based growth from our key innovative products across species and geographies and we remain very positive on the remainder of the year and beyond.
Speaker Change: Our guidance combined with our year to date results does signal some expected deceleration in our revenue growth rate for Q4, specifically.
Speaker Change: As a reminder, revenue growth in Q4 will be impacted by the MSI divestiture, reflecting a reduction of two months of U S sales and one month from our international business out of our results in Q4.
Additionally, we also saw the impact of stocking from the launch.
Speaker Change: Both of the boiler and <unk> in Q4 of last year.
Speaker Change: Normalizing for these items Q4 will be more in line with our historical growth rates.
Speaker Change: We remain confident in underlying demand and market dynamics as we move into the fourth quarter and then 2025.
Speaker Change: Our outlook for next year remains positive.
Speaker Change: We continue to see favorable trends in our key franchises, including OE, dermatology and <unk> as well as momentum from alternative channels.
Speaker Change: While we anticipate the recent tailwind from higher inflation to normalize our recent performance has significantly outpaced price driven gains alone.
Speaker Change: Additionally, we expect headwinds in China to normalize in Q4 and moving into next year.
Speaker Change: We estimate these headwinds have had approximately a one percentage unfavorable impact to our growth this year that should normalize in 2025.
Speaker Change: We are confident in our continued ability to grow above the animal health market driven by the strength of our portfolio pipeline and our dedicated colleagues.
Speaker Change: Now I'll hand things over to the operator to open the lines for your questions.
Speaker Change: Operator.
Speaker Change: At this time, if you would like to ask a question. Please press star one now on your telephone keypad to withdraw yourself from the queue Press Star two.
Speaker Change: In the interest of time, we ask that you limit yourself to one question and then queue up again with any follow up.
Speaker Change: Thank you.
Speaker Change: We'll take our first question from Erin Wright of Morgan Stanley.
Erin Wright: Great. Thanks for taking my question is a two parter here two first on <unk>, how should we be thinking about the quarterly progression from here in terms of U S flight Birla in how has the experience been in terms of reorder rates in the months on therapy relative to your internal expectations and then.
Erin Wright: How we should think about that quarterly progression given the stocking dynamics in the fourth quarter and into 2025, and then as we think about bigger picture here just several moving pieces into 2020.
Erin Wright: 2025 from a profit perspective.
Erin Wright: Yes, you continue to invest in innovation library with scale you have favorable mix also from MSA sale like how do you think about the level of investment that you need to make next year and sort of how much you're gonna, let sort of enhanced product mix more skewed towards that companion animal actually flow through in terms of margin expansion next year as well.
Speaker Change: So how do you think about those the headwinds and tailwind I guess into 2025.
Speaker Change: Thanks, Aaron I'll start with overall umbrella and move to Whitney on sort of quarterly cadence in 2025 question you had.
Speaker Change: We are really pleased with the performance globally with labella with 123% growth really remain committed to being a 1 billion dollar franchise and as you look at just the quarterly progression to date, it's been the most successful launch in our company's history in the U S. We have an 85% penetration rates globally, we're averaging over nine.
Speaker Change: Andy.
Speaker Change: In the first 12 months, we've already got 1 million patients on the product and we believe we've got a significant runway for growth with only 1 million patients on that an $8 million still on and said.
Speaker Change: We think there's a really large addressable market, we can focus on higher compliance. So we were very optimistic on that I'll, let let me get into the quarterly cadence going forward as well as your 2025 question as well.
Speaker Change: And as Christian said, the boiler has been our most successful launch in the history of the company by every metric that we look at.
Speaker Change: Colin penetration and also the first 12 months revenue.
Speaker Change: And then approximately $192 million now as you know, we don't tend to give guidance down to an individual product for an individual quarter, but what I would say in terms of the cadence of of the Wella is that we'll continue to see it.
Speaker Change: Exiting this year into next year.
Speaker Change: Starting to see strong growth given our penetration as Kristian said about $1 million being treated compared to end says it all at about $8 million and so.
Speaker Change: We know launching these major franchises that are new standards of care.
Speaker Change: Take time and one other item that is.
Speaker Change: Sydney clear when you look at their historical visits.
Speaker Change: Visits around OA pain as Christian said in the prepared commentary, we do tend to see a peak in Q2 coming down in Q3, and then typically comes back up a bit in Q4, but not to the level of Q2. So that's another element that I would give you to sort of consider as you think about what to expect through the end of the year.
Speaker Change: And going into 2025 now with respect to your second part of your question around considerations.
Speaker Change: Considerations and profitability et cetera, but we continue to demonstrate an ability to grow above the animal health market and we certainly see that in our performance. This year on a year to date basis. We're at 12%. We just raised guidance again for the third time this year clearly well above the market and are growing or just an income faster than our top.
Speaker Change: I'm, including in this quarter, which as you recall last call. We highlighted the fact that we are increasing some of our investments as we exit this year and we still delivered faster.
Speaker Change: Adjusted net income and so as we look ahead. This is a core tenant of our value proposition that will continue to be mindful of and we have the opportunity here as we look ahead to leverage investments we've made in the past, including field force investments in the U S and we see opportunity to continue to leverage those even as we continue to drive growth and launch products across the market we will.
Speaker Change: So you do see some investments in DTC behind our key brands again, we're building a market something we've demonstrated ability to build the market expand them and defend them. If you look at what we're doing across our portfolio right now an important part of that will be DTC and advertising promotion behind these products as we go into next year, we would anticipate.
Speaker Change: Again, as I've said before the business has an inherent ability to grow the bottom line faster than the top as you see the mix as well as price that we're able to take how much we deliver in any given year may vary depending on the level of investments, we're making but we remain committed to growing the bottom line faster.
Speaker Change: Our next question is from Michael Riskin of Bank of America.
Michael Riskin: Great. Thanks for taking the question guys and I want to follow up on a couple of points you touched on there first.
Michael Riskin: Just in the quarter.
Michael Riskin: Thinking about a library of progression year to date I know you had some stocking destocking dynamics earlier in the year, just making sure for Libra for trio for Durham was there anything like that in the third quarter in terms of inventory management with customers people stocking for year end or maybe destocking any promotions or anything like that.
Speaker Change: I just want to make sure that we're looking at a quote unquote clean numbers here, especially with some competing which is going on for some of these things and then two I wanted to ask you a little bit on the MSA component.
Speaker Change: Updated the guide for that divestment for the fourth quarter as you touched on two months in the U S. One O U S. How should we think about full year 2025 impact in terms of updating our numbers.
Speaker Change: I think it's roughly $350 million annual revenues, but and you can see in terms of how much SG&A spend how much R&D spend.
Speaker Change: Falls into that.
Speaker Change: So we just have to true up our models for next year. Thanks sure.
Speaker Change: It was a clean quarter across our entire business in the U S and abroad. So there's no stocking dynamics, our inventory buildups in there, but I'll, let you take the more detailed question on Msas, Yes, sure look to Christians point.
Speaker Change: If you look at inventory levels, particularly across distributors in the U S, which we have visibility into not as much visibility obviously across clinics individually, but our inventory levels remain closer to the low end of our historical averages.
Speaker Change: Similar to where we were.
Speaker Change: Over a year ago in Q1 after the Destocking. So I would say that and then with whom we labella keep in mind. This is a cold chain product.
Speaker Change: Is being shipped direct with clinics and not going through distribution. So it's really a product and given our penetration levels that we highlighted two quarters ago does not incremental penetration to really influence inventory levels here. So I thought I would add that to the to the answer you already received.
Speaker Change: <unk> just a reminder of what we have.
Speaker Change: Disclosed previously this is a business last year of 2023 full year did about $400 million and about 30% margins. So I think that gives you and by the way of seasonality here is roughly linear across the year. So if you look at the divestiture this year its about half of a quarter.
Speaker Change: With two months of the U S and one month of international you can run the numbers here in terms of what the impact is exiting this year.
Speaker Change: And then what that would be for next year, because we'd have $3 five quarters in the number in 2024 that we will be comping against and I think that should give you, even though I'm not getting into specifics on SG&A versus R&D etcetera, I think that gives you an impact through the P&L.
Speaker Change: Our next question is from Brandon Vazquez William.
Speaker Change: William Blair.
Speaker Change: Hi, everyone. Thanks for taking my question I wanted to focus on parasiticide disappearing trio, it's been a really strong segment for you guys, especially trio can you talk a little bit about despite more competition in the market. Why are you guys seem to be taking care of perhaps that's something.
Speaker Change: On the commercial side and maybe some of the execution you guys have there. So just any color there and how much that can continue into 'twenty five and then a quick follow up is just if theres any what me for you if theres any price mix commentary you can give us on the quarter, especially in the companion animal side. Thank you.
Speaker Change: Sure. Thanks, Brendan look we're really proud of the performance of trio. It is the number one prescribed parasiticide and it's already been used in over 13 million dogs.
Speaker Change: I think that the real focus here for us is <unk> growing 27%.
Speaker Change: Globally is really.
Speaker Change: Having a phenomenal product I think it starts with that I think we were first to market with trio, which I think has made a big difference.
Speaker Change: We've also been able to grow that product tremendously leveraging alternative channels, which today is about 20% of that but I think what's really under underscoring all of this is that oh, the oral flea tick and heartworm market is growing 45% year over year and that growth is moving more people into the oral category and as you will get puppy share, which I think is it.
Speaker Change: Really good indicator of where we're going in the future trio has a 35% share and puppies. So I think between being a first mover advantage, having a phenomenal product that's got comprehensive coverage it's convenient it's at.
Speaker Change: <unk> I think it's a great product and look we partner very closely with all of our customers and certainly with our corporate and I think youre seeing the customers are really pleased with the product. So we see strong momentum going into next year and I'll underscore some of the comments that Whitney said in his prepared remarks, which is what we've seen continuously as new entrants enter the market is the.
Speaker Change: <unk> of the oral flea tick and heartworm market and that is what we're expecting next year into 2025. So what can you do you want to take the second half of the question sure in terms of price mix and volume here as you heard in the prepared commentary the 14% operational growth in the quarter was 8% volume and 6% price now your question if it is related specifically.
Speaker Change: To a person size in the trio performance I would say, it's about balanced with a slightly more volume than price here and keep in mind as we've stated previously.
Speaker Change: We have more targeted.
Speaker Change: Promotions as well as discounts to our customers, which is actually driving better price realization and not just price increases. If you will hear on this product, which again has been a phenomenal execution I would say and contribution to the growth that you're seeing on <unk> specifically.
Speaker Change: Our next question is from Jon block of Stifel.
Jon Block: Thanks, guys good morning.
Jon Block: First one.
Jon Block: Are there any different marching orders for the sales force is U S Library.
Jon Block: Now largely moves from call it new practice adoption to more driving utilization and getting into mild to moderate maybe the tack on to that would be any specific thoughts about <unk> revenue from U S.
Jon Block: <unk> did you commit to Q over Q growth because.
Speaker Change: I just wanted to follow up there seems to be the only noise in the quarter quite honestly and then the second one would just be any high level building blocks for 2025 revenue.
Speaker Change: You mentioned, China headwinds of a point this year I'm guessing for the most part that unwind.
Speaker Change: Got library of other trajectory obviously some of the other key franchises. So again, even at a high level any building block for us to take into consideration. Thanks guys.
Jon Block: Sure.
I would say, there's not any new sales marching orders I think it's a lot more of continuing to focus on getting clinics have more experience across not just sitting here, but moving into moderate which means started probably a little while ago that was a key focus even for us at launch. So we'll continue to focus on growing the brand there, but I think it's really sticking with the key messages.
Jon Block: The safety of the product the efficacy of the product and really demonstrating continuously the opportunity to look at the 8 million patients currently on and says and switching those <unk> patients over to labella, assuming that that's the right product for that pet overall, so we remain very very pleased with this launch and.
Jon Block: Given how clean your ankle launch I think we're going to continue down the same tactics that we have certainly now that we've got the penetration, it's really focusing on expanding the Hughes.
Jon Block: Adam just not severe but obviously in moderate as well as you know really talking about the opportunity given the different pets medical needs to switch from Ensign. So I'll take the second part of the question over to Whitney on building block for 'twenty.
John look we look forward to sharing our 2025 guidance on our next call in February.
Whitney: And just maybe a few reminders here that might be helpful. In terms of Directionally, where we're headed right. We have several sources of growth and we're continuing to see strong underlying demand across our portfolio in most markets, where we operate.
Whitney: Our outlook for Derm and <unk> remained very positive.
Whitney: Getting this year and going into next year.
Jon Block: We expect to see continued strong growth across our OA pain franchise on a year over year basis and <unk>.
Jon Block: Even if you have more normalized pricing, we would expect those to be above.
Jon Block: Slightly above our historical pricing contribution of 2% to 3%.
Jon Block: And as I covered in the prepared commentary China will be more normalized as we exit this year starting in Q4 and into next year and so you have less of a headwind.
Jon Block: Going into next year, which was almost a full point in the current year. The last piece I would give is just a reminder, on the MFA and water soluble product portfolio, removing dosing that shared those numbers already in terms of with it those are part of that last year. So hopefully that's helpful. In terms of getting you into some sort of ballpark here.
Speaker Change: Our next question is from David Westenburg of Piper Sandler.
David Westenburg: Hi, Thank you for taking the question and congrats on a great quarter.
David Westenburg: Just a little bit touch on macro real quick just in terms of.
David Westenburg: How you price relative to veterinary CPI is that ever a consideration and as we go into next year do you also consider some of the clinic growth assumptions that we've seen yes, you are isolated in a lot of ways. Because you can buy off off channel. However, those initial scripts do need to come on visits and we've seen visits for.
David Westenburg: The last year being <unk>.
Speaker Change: Quite down now and then just a second on a clarification Whitney I think you said in your prepared remarks, a reasonable promotion environment or something along the lines of that can you clarify what you mean, if you meant so whether it's an industry wide and specifically I'm thinking about some of the promotion environment beginning of next year as we enter parasiticide season.
Jon Block: You'll have a full season of cuatro.
Jon Block: Might be lapping some of the promotions from from next card plus I don't know of anything like that so if I could just get a clarity there. Thank you.
Whitney: Sure. Thanks, David I'll start with your first one and let me if I Miss anything please build on it.
Speaker Change: If we think about pricing, obviously, we start with the pricing environment and you know the overall inflation environment of any given market, where we compete but the primary thing that we really focus on is a product by product SKU by SKU, you view of our differentiation in the marketplace overall and I know you referenced that you know visits were down I mean, we continue to say visit.
Whitney: They're not a good proxy for how animal health and more particularly how does the what it does.
Whitney: Really what you're seeing in some of those wellness visits and a lot of those are products pick up products and visits and a lot of that is going over to the alternative channel, which continues to grow very strongly but as you look at the visits for our particular products around derm or around pain Theyre up and so I think we were really focused on what is the innovation.
Whitney: And what is the value that our product provides to both the vet and the pet owner and I think that is what really primarily drive our pricing strategy. Overall I will turn the second question on there a pricing or the promotional environment to your Buddy sure look the only thing I would add to the visits is even as overall visits are down in the U S. If you look at the key.
Whitney: Therapeutic areas for us OA pain visits are up double digits.
Whitney: Visits are up even as more and more of our Africa, what products are being sold through the retail channel. So I think that really spills and consistent with what we've been sharing for some time now.
Whitney: And then if you look at alternative channels and that's been a significant growth driver for us of course, the U S pet care, which of course reduces some of the dependency on clearing visits as well as the auto ship and higher compliance that that drives alternative channels were up actually 34% year on year on the quarter again demonstrating that points.
Whitney: Far as promotional activities. My comment here is you see far more disciplined promotional environment. This year, particularly when you compare it to last year. When we were up against a new competitor in the Triple combination parasiticide space. So that comment was really to say theres not as much promotional activity here and that we were more targeted in.
Whitney: Terms of our discounting to our customers.
Speaker Change: Our next question is from <unk> Prasad of Barclays.
Speaker Change: Hi, good morning, and thanks for taking the questions.
Prasad: Two from me one speaking a bit more about 2025 could you comment Bob comment on the incremental drilled dry wasn't headwinds, especially that you see in 2025.
Prasad: And especially as we think about Opex again don't want to get into guidance, but if you can just comment on the pushes and pulls dwarves, our opex plan in the.
Prasad: Secondly, with regard to entire country ill again can you comment on what kind of move in terms of the $57 million 50 million Doug Doug since you provided that could move to Isoxazole ends.
Prasad: What's the pace of conversion that could be achieved on a realistic basis. Thanks.
Speaker Change: Sure what made you want to take that sure.
The first point in terms of next year and again I look forward to providing more specific guidance in February here.
Prasad: Look I think as we've said in Investor day, we see opportunity to leverage our.
Prasad: G&A from a opex perspective, we have been running R&D driven by our portfolio and.
Prasad: Our pipeline progression.
Whitney: Faster than revenue I think you see that coming in closer to revenue this year.
Prasad: We will get into more more detailed than that in terms of what we would expect into next year, but that's certainly one consideration I think when I think about other pushes and pulls there has been a lot of conversations around Argentina. This year.
Jon Block: I think one thing to keep in mind is as we have highlighted the pricing that we've taken in Argentina. This year, you'll get in hyper if other hyperinflationary markets for that matter again.
Jon Block: Expect a more normalized pricing environment.
Jon Block: We would anticipate slightly above where our historical rate is that incremental price you see from Argentina. This year, which is actually on a declining basis.
Jon Block: Q1 was the peak we've come down in Q2 and into Q3, and we expect Q4 to be closer to 1% I think that would be an item to consider as we go through next year, but one important point, though is if you walk down the P&L that is actually had.
Jon Block: Significant headwinds through inflation through the middle of the P&L and then from an FX perspective, if you look at the reported results the net impact of Argentina year over year is actually negative across the P&L. So I think thats really important point to keep in mind as you're thinking about SG&A and then the other point on as we look at the press suicides.
Jon Block: Market and what we expect to happen here. We've seen this before this is the same that we saw.
Jon Block: It almost a decade ago with the launch of <unk>.
Jon Block: It's also leans you saw really continual transition into those that continue to grow the market substantially and clearly when we look at the percentage of puppies. Good are getting put on a triple combination which is much higher than the overall percentage.
Jon Block: Of dogs that are on Paris, So about a third of the prescription Paris suicides are in triple combinations, but over 50% of puppies are and so that gives you a strong indication of what's going to continue to happen in that market. The split between how much is going from although olds versus collars and topic as it is not something we have a special.
Jon Block: Specific on but needless to say that is where the market is going is towards those triple combinations. Yeah. In Appalachia I just encourage you to look at our slides for today's because we can show you. Some of the graphs of what that actually it looks like and I think with that double digit growth of fourth year on the market I think it speaks for itself as well.
Speaker Change: Our next question comes from Glen Santangelo of Jefferies.
Glen Santangelo: Yes, Thanks for taking my question Kristen It sounds like the companies and confident in its ability to take another year of above average price increases and I'm kind of curious like what what's sort of giving you that confidence and given the evolving competitive landscape in <unk>.
Jon Block: Current macro climate and then just as sort of part of that could you give us an update on what percentage of the companion business is flowing through alternate site versus the vet office and if that's having any impact on any sort of pricing or customer trends that we should be aware of thanks.
Speaker Change: Sure I'll start with your second question retail grew 34% I think it's a little bit over I mean, you can correct me around 10% of the U S.
Speaker Change: Business at this point, what does that require higher its closer to 15%. If you look at alternative channels.
Jon Block: Retail.
Jon Block: Online as well as looking more at home delivery as well combined yeah. No I think it's growing very very strongly in the U S. I mean look as we look at overall pricing again I go back to where I said before which is we look product by product and the innovation, we're bringing in I think what we really talked about continuously is that adverse durable and innovative portfolio than what it has across species.
Jon Block: And globally and so we that's how we price our products.
Jon Block: And we've continued as we've seen competition for example, in parasiticide and continuously taking price there as well, where we see the convenience and.
Jon Block: The benefits that <unk> offers so I don't have anything new to either I'm not sure what any if you do look I think if you look at this year right.
Jon Block: We are taking price if you take Argentina out its somewhere in the four 5% to 5% range across the rest of our portfolio rate and despite that you see significant volume growth. This quarter I think it's a testament to that 8% volume growth and 6% price and so if you look at our key product areas and keep their arm.
Jon Block: You see price as well as substantial volume growth. So we think theres room for us to continue that given the value that we bring.
Jon Block: With these innovations.
Speaker Change: Our next question is from Chris Schott of Jpmorgan.
Chris Schott: Oh, great. Thanks, just two questions from me maybe first on <unk> can you just elaborate a little bit about how youre thinking about the impact from the centrella launch and maybe specifically should we anticipate any slowdown to your growth due to some of their promotional activities.
Jon Block: Relatively limited impact there and then my second question would be on Labella uptake just any comments of how U S. Compliance is trending relative to your expectations I know, it's early but just anything notable in some of those initial trends. Thank you.
Speaker Change: Sure I'll start with Apple Carl and I wasn't sure. If you want to build on labella uptake question, yet another strong quarter, obviously from <unk>.
Jon Block: We had 16% growth across the quarter I think.
Jon Block: The number one product out there, it's got 11 years of safety.
Whitney: Huge satisfaction rates across both consumers and veterinarians with a 90% satisfaction rate and I think our focus is the product is continuing to grow the category. We think there's an opportunity for higher compliance to address under untreated dogs to convert the $3 million or on other treatments on 8 million dogs are currently not on therapy.
Whitney: We're very confident in our ability to compete with this product given the satisfaction given the safety and given the efficacy overall, we're very proud of the performance of that and we look forward to a strong performance, obviously going forward in 2025 and beyond.
Speaker Change: Yeah sure look I think as we've said before this is our most successful launch ever in the company's history, and I think while it's a little bit early to get into a ton of detail around compliance in the U S. Specifically I always like to look at our international markets, which will continue to see strong double digit growth across those markets for years.
Speaker Change: Our when we look at the transition into more moderate cases, which now represent more than 60% of our of cases and Internet of course Europe. For example, that's driving up months on therapy to be above seven months.
Jon Block: And our compliance rates.
Jon Block: <unk> really high in that market. So I think this gives you an indication of where the market is and given the.
Jon Block: The efficacy and the revolutionary profile of this product what it what it can do and what is actually doing across markets outside the U S. And we're very pleased with where we are in the launch trajectory here in the U S as well.
Speaker Change: Our next question is from Steve Scala of TD Cowen.
Speaker Change: Hi, This is Chris on for Steve Congrats on the strong quarter and thanks for taking our questions.
Jon Block: The latest is its best competence and above industry average sales growth what is your level of confidence in being able to maintain this growth long term based only on current unmet at Fedex without contributions from pipeline of business development and then second how many competitive markets are you expecting in 2025 and how is this uncertainty impacting your thoughts on how concerned.
Jon Block: Initial 2025 guidance for me thank you.
Speaker Change: Sure I'll give that a shot look I think if you look at our history over a decade, we have outperformed the market.
Speaker Change: Three points on average.
Jon Block: Would argue if you look at the market growth rates. This year, it's even above that now to your question is how what's our confidence level and be able to sustain that we're very confident in our ability to sustain that given our existing portfolio and bifurcate it between existing portfolio and new launches is not something I am going to venture into because that is ingrained into how we go to market and how we can.
Jon Block: We need to invest.
Jon Block: In solving for our customers' greatest challenges, it's hard for me to give you what the growth would be without that but what I would say is it's really important to note that it's not only when we launch a brand new innovation and new area is the continued lifecycle innovation that we drive which is almost historically, 50% of R&D spend so we can see.
Jon Block: To grow the market and extend the market, adding additional claims as.
Jon Block: As we go along the way, which is how we over time build markets and I know, there's a lot of questions around sequential growth et cetera, it's not really about the sequential growth never really super linear it's over time building the market that once you build it is also very sticky because you've established this standard.
Jon Block: And someone else has to come with something that is significantly differentiated in order to overtake you and that's what drives our business. So we're very confident in continuing to be able to outperform the industry.
Speaker Change: And once again that is star one to ask a question, we'll move next to Navan tie of BNP Paribas.
Navan tie: Hi, good morning, Thanks for taking my question.
Navan tie: One on competition and one on innovation. So on competition can you expand on which leather.
Jon Block: So it is using to defend our book while this has been the year would that be or is it DTC about the safety as well as near term pricing or anything else and for <unk> do you plan any promotions around that launch maybe to a lesser extend that when you are facing a next door plus and then on innovation.
Jon Block: Are you able to discuss progress around around the long acting injectable monoclonal antibodies and how does it differ.
Jon Block: And longer term.
Jon Block: In <unk> oncology and cardiology. Thank you.
Speaker Change: Sure with regards to the competition and your first question I think was on the derm space.
Speaker Change: We remain very confident in our ability to continue to grow our overall dermatology franchise, whether that's <unk> apical chewable or cited point, even with the new competition. We think again, our 11 years of safety and efficacy competing against a product with a box warning.
Speaker Change: I think it is quite strong I think our satisfaction. We will continue to do the same tactics. We always said, we don't see any need to change any of those that's really around building deep relationships with our customers sharing the performance of the product investing in direct to consumer we don't really see a need given the competition either within really are also Cordelia cuatro.
Well, we continue to see as Whitney.
Speaker Change: Remarked in his opening statement is that really when new entrants come it grows the market overall, they invest more in direct to consumer advertising and we will see more of a conversion over to the oral I talked Abilene class, though we remain very confident we're not planning on changing any of our promotional tactics. When you think about <unk>.
Speaker Change: They entered in derm as well as the initial entry.
Speaker Change: And to the parent and look we expect everyone will enter Paris and that will only grow the category overall as you think about innovation as we talked about at our Investor day, we really see long acting across all of our key franchises is an important driver of growth we haven't given specific guidance on when those launches will be but those would be more of a near term launches as we've mentioned in previous session.
Speaker Change: Yes.
Speaker Change: Okay.
Speaker Change: And there are no further questions at this time I'd be happy to return the call to Kristin Peck for closing comments.
Kristin Peck: Thanks, and thank you all for joining us as always we really appreciate your questions and importantly, your interest in <unk>.
Kristin Peck: The animal health industries are prudently proven its resilience and Arbor work remains essential not only for animals, but for the people and the communities and the economies impacted globally. So looking ahead. We are excited to strengthen our market leadership by leveraging this resilience and driving long term growth and value creation and with that I want to thank you for your.
Kristin Peck: Continued trust as you move forward with confidence and purpose committed to shaping the future of animal health. Thanks for joining us.
Speaker Change: Thank you. This does conclude today's call you may now disconnect and everyone have a great day.
Speaker Change:
Speaker Change: Mhm mhm.
Speaker Change: Uh-huh.
Speaker Change: [music].
Speaker Change: Hum.
Speaker Change: [music].